GlassScriptPhysician profile
Edmund Farris
NPI 1881646552
$20,648.92
in general payments reported to CMS, 2019-2025
23 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $673 · 2021: $3,277 · 2022: $1,931 · 2023: $336 · 2024: $1,392 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,212 · Consulting Fee: $6,000 · Travel and Lodging: $658 · Education: $15.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,211.75 |
| Consulting Fee | $6,000.00 |
| Travel and Lodging | $658.35 |
| Education | $15.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $7,356.59 | 2025 | Travoprost Intraocular Implant - Idose, Idosetr |
| Eyevance Pharmaceuticals LLC | $3,010.83 | 2019-2022 | |
| Abbvie INC. | $2,533.39 | 2022-2025 | |
| Alcon Vision LLC | $1,723.77 | 2019-2025 | Clareon, Rocklatan, Unity |
| Lumenis Be INC | $1,650.00 | 2025 | M22 |
| Harrow Eye, LLC | $1,043.47 | 2024-2025 | |
| Allergan, INC. | $707.94 | 2019-2022 | |
| Amgen INC. | $340.01 | 2024-2025 | Tepezza, Uplizna |
| Dompe US, INC. | $310.67 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $294.10 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $259.77 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $204.10 | 2019-2022 | |
| Galderma Laboratories, L.P. | $202.65 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $201.94 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $170.16 | 2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $124.30 | 2019 | |
| Mallinckrodt Hospital Products INC. | $122.81 | 2024 | Acthar |
| Horizon Therapeutics Plc | $121.84 | 2021 | |
| Oyster Point Pharma, INC. | $118.24 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $71.58 | 2023-2025 | Vyzulta, Xiidra, Miebo |
| Kala Pharmaceuticals, INC. | $31.05 | 2019-2021 | |
| Thea Pharma INC. | $29.67 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.